Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

Back in 2017, be­fore the term “tu­mor ag­nos­tic” re­al­ly took hold among can­cer drug de­vel­op­ers, Mer­ck be­came the first to se­cure such an ap­proval for Keytru­da as a sec­ond-line treat­ment for pa­tients char­ac­ter­ized by a bio­mark­er — rather than where the can­cer start­ed in the body. Now it’s look­ing to break fresh ground with a new slate of da­ta sug­gest­ing the drug’s util­i­ty in the front­line set­ting for col­orec­tal can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.